Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgios Schoretsanitis

Showing results (1-10 of 211) with videos related to

Pageof 22
Sort By:
Therapeutic Drug Monitoring|February 20, 2024
Establishing and Extending the Use of Therapeutic Drug Monitoring in NeuropsychopharmacologyGeorgios Schoretsanitis,
Der Nervenarzt|November 7, 2025
[Plea for an appropriately dosed antipsychotic psychopharmacotherapy using haloperidol as an example]Michael Paulzen, Georgios Schoretsanitis
Der Nervenarzt|July 14, 2023
[Psychopharmacotherapy during pregnancy and breastfeeding-Part II: focus on breastfeeding : Support options by using therapeutic drug monitoring]Michael Paulzen, Georgios Schoretsanitis
Der Nervenarzt|July 17, 2023
[Psychopharmacotherapy during pregnancy and breastfeeding-Part I: focus on pregnancy : Support options by using therapeutic drug monitoring]Michael Paulzen, Georgios Schoretsanitis
Der Nervenarzt|March 30, 2026
[Olanzapine long acting injectable in new application form-Hope for the absence of post-injection delirium/sedation syndromes]Michael Paulzen, Georgios Schoretsanitis
Current Opinion in Psychiatry|November 6, 2025
Utility of therapeutic drug monitoring in the treatment of major depressive disorderGeorgios Schoretsanitis, Michael Paulzen
Therapeutische Umschau. Revue Therapeutique|March 25, 2026
[Optimisation of psychopharmacological treatment strategies by using therapeutic drug monitoring]Michael Paulzen, Georgios Schoretsanitis
Pharmacogenomics|October 15, 2020
CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of researchJose de Leon, Georgios Schoretsanitis
The Journal of Clinical Psychiatry|July 8, 2022
Best Practices for Starting Clozapine in Patients With Schizophrenia: How to Switch From the Prior Antipsychotic(s)Georgios Schoretsanitis, Jose de Leon
Expert Opinion on Drug Metabolism & Toxicology|February 28, 2025
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophreniaGeorgios Schoretsanitis, Christoph U Correll
Pageof 22

Showing results (1-10 of 211) with videos related to

Sort By:
Pageof 22
Therapeutic Drug Monitoring|February 20, 2024
Establishing and Extending the Use of Therapeutic Drug Monitoring in NeuropsychopharmacologyGeorgios Schoretsanitis,
Der Nervenarzt|November 7, 2025
[Plea for an appropriately dosed antipsychotic psychopharmacotherapy using haloperidol as an example]Michael Paulzen, Georgios Schoretsanitis
Der Nervenarzt|July 14, 2023
[Psychopharmacotherapy during pregnancy and breastfeeding-Part II: focus on breastfeeding : Support options by using therapeutic drug monitoring]Michael Paulzen, Georgios Schoretsanitis
Der Nervenarzt|July 17, 2023
[Psychopharmacotherapy during pregnancy and breastfeeding-Part I: focus on pregnancy : Support options by using therapeutic drug monitoring]Michael Paulzen, Georgios Schoretsanitis
Der Nervenarzt|March 30, 2026
[Olanzapine long acting injectable in new application form-Hope for the absence of post-injection delirium/sedation syndromes]Michael Paulzen, Georgios Schoretsanitis
Current Opinion in Psychiatry|November 6, 2025
Utility of therapeutic drug monitoring in the treatment of major depressive disorderGeorgios Schoretsanitis, Michael Paulzen
Therapeutische Umschau. Revue Therapeutique|March 25, 2026
[Optimisation of psychopharmacological treatment strategies by using therapeutic drug monitoring]Michael Paulzen, Georgios Schoretsanitis
Pharmacogenomics|October 15, 2020
CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of researchJose de Leon, Georgios Schoretsanitis
The Journal of Clinical Psychiatry|July 8, 2022
Best Practices for Starting Clozapine in Patients With Schizophrenia: How to Switch From the Prior Antipsychotic(s)Georgios Schoretsanitis, Jose de Leon
Expert Opinion on Drug Metabolism & Toxicology|February 28, 2025
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophreniaGeorgios Schoretsanitis, Christoph U Correll
Pageof 22